Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL11750618 | 1.00 | CA2 (0.54) | — | |
| Water SCHEMBL1697235 | 1.00 | CA2 (0.54) | — | |
| Water SCHEMBL9333419 | 1.00 | — | — | |
| Water SCHEMBL7032487 | 1.00 | CA2 (0.54) | — | |
| Water SCHEMBL1120078 | 1.00 | — | — | |
| Water SCHEMBL8140555 | 1.00 | CA2 (0.54) | — | |
| Water SCHEMBL660657 | 1.00 | — | — | |
| Water SCHEMBL22581621 | 0.95 | — | — | |
| Water SCHEMBL22581609 | 0.95 | — | — | |
| Water SCHEMBL10342957 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3297609-A1 | PHARMACEUTICAL COMPOSITIONS | Novartis AG (CH) | 2018-03-28 | — | — | EP | claimed |
| CN-107847448-A | Pharmaceutical composition | 诺华股份有限公司 | 2018-03-27 | — | — | CN | claimed |
| WO-2016189435-A1 | PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2016-12-01 | — | — | WO | claimed |
| CN-1210262-C | Method for preparing mesylate salt trihydrate of 1- (4-hydroxyphenyl) -2- (4-hydroxy-4-phenylpiperidin-1-yl) -1-propanol | PFIZER PROD INC (US) | 2005-07-13 | — | — | CN | claimed |
| CN-1193036-C | Method of preparing clarithromycin of form II crystals | HANMI PHARM IND CO LTD (KR) | 2005-03-16 | — | — | CN | claimed |
| EP-1151995-B1 | Process for the preparation of the mesylate salt trihydrate of 1-(4-Hydroxyphenyl)-2-(4-Hydroxy-4-Phenylpiperidin-1-YL)-1-Propanol | PFIZER PROD INC (US) | 2004-09-22 | — | — | EP | claimed |
| EP-1149831-B1 | Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol and intermediates useful therefor | PFIZER PROD INC (US) | 2004-09-01 | — | — | EP | claimed |
| US-6645986-B2 | Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol | PFIZER PRODUCTS, INC. | 2003-11-11 | — | — | US | claimed |
| CN-1429233-A | Method of preparing clarithromycin of form II crystals | HANMI PHARM IND CO LTD (KR) | 2003-07-09 | — | — | CN | claimed |
| US-6570018-B2 | Reducing the propanone of the compound with an alkali metal borohydride and cleaving the protecting group in the presence of methanesulfonic acid; n-methyl-d-aspartic acid receptor antagonist; longer shelf life | PFIZER INC | 2003-05-27 | — | — | US | claimed |
| US-20020016466-A1 | Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol and intermediates useful therefor | PFIZER INC. | 2002-02-07 | — | — | US | claimed |
| CN-1321638-A | Method for preparing mesylate salt trihydrate of 1- (4-hydroxyphenyl) -2- (4-hydroxy-4-phenylpiperidin-1-yl) -1-propanol | PFIZER PROD INC (US) | 2001-11-14 | — | — | CN | claimed |
| EP-1151995-A1 | Process for the preparation of the mesylate salt trihydrate of 1-(4-Hydroxyphenyl)-2-(4-Hydroxy-4-Phenylpiperidin-1-YL)-1-Propanol | Pfizer Products Inc. (US) | 2001-11-07 | — | — | EP | claimed |
| EP-1149831-A1 | Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol and intermediates useful therefor | Pfizer Products Inc. (US) | 2001-10-31 | — | — | EP | claimed |
| US-6008233-A | TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | PFIZER INC (US) | 1999-12-28 | — | — | US | claimed |
| CN-1198739-A | (1S,2S) -1- (4-hydroxyphenyl) -2- (4-hydroxy-4-phenylpiperidin-1-yl) -1-propanol mesylate trihydrate | PFIZER (US) | 1998-11-11 | — | — | CN | claimed |
| EP-0843661-A1 | (1S,2S)-1-(4-HYDROXYPHENYL)-2-(4-HYDROXY-4-PHENYLPIPERIDIN-1-YL)-1-PROPANOLMETHANESULFONATE TRIHYDRATE | PFIZER INC. (US) | 1998-05-27 | — | — | EP | claimed |
| US-5716961-A | Treatment of tinnitus using neuroprotective agents | PFIZER INC. (US) | 1998-02-10 | — | — | US | claimed |
| EP-0768086-A1 | Treatment of tinnitus using neuroprotective agents | PFIZER INC. (US) | 1997-04-16 | — | — | EP | claimed |
| WO-1997007098-A1 | (1S,2S)-1-(4-HYDROXYPHENYL)-2-(4-HYDROXY-4-PHENYLPIPERIDIN-1-YL)-1-PROPANOLMETHANESULFONATE TRIHYDRATE | PFIZER INC. (US) | 1997-02-27 | — | — | WO | claimed |